Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.61 |
| ▸ | PPARG | P37231 | 9/20 | 0.61 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092840 | 1.00 | PPARA (0.61) | PPARAPPARGPPARDFFAR1ESR1 | |
| SCHEMBL3115791 | 1.00 | PPARA (0.61) | PPARAPPARGPPARDFFAR1ESR1 | |
| SCHEMBL6091611 | 0.93 | PPARA (0.54) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL14064975 | 0.93 | PPARA (0.62) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3947028 | 0.92 | PPARA (0.72) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3938267 | 0.91 | PPARA (0.61) | PPARAPPARGFFAR1 | |
| SCHEMBL3100619 | 0.90 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3946198 | 0.90 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL13156113 | 0.90 | PPARA (0.60) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3100628 | 0.90 | PPARA (0.71) | PPARAPPARGPPARDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803586-B2 | Chemical Process | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| EP-1458677-B1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-7429675-B2 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid | ASTRAZENECA AB (SE) | 2008-09-30 | — | — | US | disclosed |
| US-20080115247-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-7276539-B2 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| EP-1828394-A2 | CHEMICAL PROCESS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070099928-A1 | Amine salts of (-)-2-{2-(4-hydroxyphenyl) ethyl]thio} -3-4-(2-{4-(methylsulfonyl) oxy phenyl propanoic acid and their use in medicine | ASTRAZENECA (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099997-A1 | Potassium or sodium salt of (-)-2-{'2-(4-hydroxyphenyl) ethyl!-thio-3-'4-(2-{4-'(methylsulfonyl) oxy! phenoxy}ethyl) phenyl! propanoic acid and their use in medicine | ASTRAZENECA (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20060167309-A1 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)pheyl]-propanoic acid | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006064213-A2 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1638930-A1 | AMINE SALTS OF (-)-2- ¬2-(4-HYDROXYPHENYL)ETHYL|-THIO -3-¬4-(2- 4-¬(METHYLSULFONYL)OXY|PHENOXY ETHYL)PHENYL|PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638927-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2004113283-A1 | AMINE SALTS OF (-)-2-{`2-(4-HYDROXYPHENYL) ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY! PHENOXY}ETHYL)PHENYL! PROPANOIC ACID AND THERE USE IN MEDICINE | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113282-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1458677-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051826-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099928-A1 | Amine salts of (-)-2-{2-(4-hydroxyphenyl) ethyl]thio} -3-4-(2-{4-(methylsulfonyl) oxy phenyl propanoic acid and their use in medicine | EP300, LIPC, CPT1A | PPARA 131/4885PPARG 481/4885PPARD 458/4885 |
| US-20070099997-A1 | Potassium or sodium salt of (-)-2-{'2-(4-hydroxyphenyl) ethyl!-thio-3-'4-(2-{4-'(methylsulfonyl) oxy! phenoxy}ethyl) phenyl! propanoic acid and their use in medicine | SLC5A2, KCNN2, SLC5A1 | PPARA 30/4885PPARG 131/4885PPARD 158/4885 |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20060167309-A1 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)pheyl]-propanoic acid | HPD, PAH, HAAO | PPARA 446/4885PPARG 1596/4885PPARD 1087/4885 |
| US-20060199857-A1 | Therapeutic agents | PNLIP, LIPC, GPR119 | PPARA 27/4885PPARG 38/4885PPARD 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.